Kiniksa Pharmaceuticals International (KNSA) Current Deferred Revenue (2022 - 2024)
Kiniksa Pharmaceuticals International (KNSA) posted Current Deferred Revenue of $31.8 million for Q4 2024, up 264991.67% on a QoQ basis from $12000.0 in Q2 2024, and up 10261.89% year-over-year from N/an in Q1 2024.
Kiniksa Pharmaceuticals International (KNSA) Current Deferred Revenue (2022 - 2024) Analysis & Trends
Kiniksa Pharmaceuticals International's Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $31.8 million for Q4 2024.
- Quarterly Current Deferred Revenue rose 10261.89% year-over-year to $31.8 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $31.8 million (up 10261.89% YoY) and the FY2024 annual result came in at $31.8 million, up 10261.89% from the prior year.
- Current Deferred Revenue was $31.8 million for Q4 2024 at Kiniksa Pharmaceuticals International, up from $12000.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $31.8 million in Q4 2024 and bottomed at $12000.0 in Q2 2024.
- A 3-year average of $7.3 million and a median of $3.6 million in 2023 frame the typical range for Current Deferred Revenue.
- Peak annual rise in Current Deferred Revenue reached 10261.89% in 2024, while the deepest fall reached 99.74% in 2024.
- Kiniksa Pharmaceuticals International's Current Deferred Revenue stood at $12.1 million in 2022, then sank by 97.46% to $307000.0 in 2023, then soared by 10261.89% to $31.8 million in 2024.
- Business Quant data shows KNSA's Current Deferred Revenue at $31.8 million in Q4 2024, $12000.0 in Q2 2024, and $156000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Kiniksa Pharmaceuticals International | 4.82 Bn | 4.36 Bn | 193.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 31.81 Mn |
| Jun 30, 2024 | 12,000.00 |
| Mar 31, 2024 | 156,000.00 |
| Dec 31, 2023 | 307,000.00 |
| Sep 30, 2023 | 2.56 Mn |
| Jun 30, 2023 | 4.67 Mn |
| Mar 31, 2023 | 6.50 Mn |
| Sep 30, 2022 | 12.09 Mn |